Cognition Therapeutics, Inc.

NasdaqGM:CGTX Stock Report

Market Cap: US$16.9m

Cognition Therapeutics Balance Sheet Health

Financial Health criteria checks 4/6

Cognition Therapeutics has a total shareholder equity of $23.0M and total debt of $185.0K, which brings its debt-to-equity ratio to 0.8%. Its total assets and total liabilities are $34.4M and $11.4M respectively.

Key information

0.8%

Debt to equity ratio

US$185.00k

Debt

Interest coverage ration/a
CashUS$28.53m
EquityUS$23.01m
Total liabilitiesUS$11.36m
Total assetsUS$34.37m

Recent financial health updates

Recent updates

Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Sep 06
Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?

Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease

Jul 31

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

May 22
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's

Apr 18

Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Nov 30
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Aug 15
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?

Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Mar 17
Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans

Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study

Sep 27

We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Aug 12
We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth

Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar

Aug 05

We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Mar 19
We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Financial Position Analysis

Short Term Liabilities: CGTX's short term assets ($33.6M) exceed its short term liabilities ($10.9M).

Long Term Liabilities: CGTX's short term assets ($33.6M) exceed its long term liabilities ($440.0K).


Debt to Equity History and Analysis

Debt Level: CGTX has more cash than its total debt.

Reducing Debt: Insufficient data to determine if CGTX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CGTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CGTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 47% each year


Discover healthy companies